IgG Endopeptidase in Highly Sensitized Patients Undergoing Transplantation
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
BACKGROUND: and Fc fragments inhibiting complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity, which suggests that IdeS might be useful for desensitization. We report on the combined experience of two independently performed open-label, phase 1-2 trials (conducted in Sweden and the United States) that assessed the efficacy of IdeS with regard to desensitization and transplantation of a kidney from an HLA-incompatible donor. METHODS: We administered IdeS to 25 highly HLA-sensitized patients (11 patients in Uppsala or Stockholm, Sweden, and 14 in Los Angeles) before the transplantation of a kidney from an HLA-incompatible donor. Frequent monitoring for adverse events, outcomes, donor-specific antibodies, and renal function was performed, as were renal biopsies. Immunosuppression after transplantation consisted of tacrolimus, mycophenolate mofetil, and glucocorticoids. Patients in the U.S. study also received intravenous immune globulin and rituximab after transplantation to prevent antibody rebound. RESULTS: Recipients in the U.S. study had a significantly longer cold ischemia time (the time elapsed between procurement of the organ and transplantation), a significantly higher rate of delayed graft function, and significantly higher levels of class I donor-specific antibodies than those in the Swedish study. A total of 38 serious adverse events occurred in 15 patients (5 events were adjudicated as being possibly related to IdeS). At transplantation, total IgG and HLA antibodies were eliminated. A total of 24 of 25 patients had perfusion of allografts after transplantation. Antibody-mediated rejection occurred in 10 patients (7 patients in the U.S. study and 3 in the Swedish study) at 2 weeks to 5 months after transplantation; all these patients had a response to treatment. One graft loss, mediated by non-HLA IgM and IgA antibodies, occurred. CONCLUSIONS: IdeS reduced or eliminated donor-specific antibodies and permitted HLA-incompatible transplantation in 24 of 25 patients. (Funded by Hansa Medical; ClinicalTrials.gov numbers, NCT02224820 , NCT02426684 , and NCT02475551 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Similarly, IdeS is an endopeptidase able to degrade circulating IgG that is currently being tested in transplant patients (123).”
From A versatile toolkit for overcoming AAV immunity (2022) · cites this paper as [123]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The global burden of group A streptococcal diseases
Carapetis, J. R., Steer, A. C., Mulholland, E. K., & Weber, M. (2005) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(05)70267-x · Cited by 2,998
Significance of the Positive Crossmatch Test in Kidney Transplantation
Patel, R., & Terasaki, P. I. (1969) · New England Journal of Medicine · doi:10.1056/nejm196904032801401 · Cited by 1,508
Haas, M., Sis, B., Racusen, L. C., Solez, K., Glotz, D., Colvin, R. B., Castro, M. C. R., David, D. S. R., David-Neto, E., Bagnasco, S. M., et al. (2014) · American Journal of Transplantation · doi:10.1111/ajt.12590 · Cited by 1,350 · cited 1×
“Scoring of various values (complement factor 4d deposition [C4d+], interstitial fibrosis and tubular atrophy [IFTA], glomerulitis plus peritubular capillaritis [GPC], transplant glomerulopathy [TG], and thrombotic microangiopathy [TMA]) was based on Banff 2013 criteria.(18) T bars indicate 1 SD.”
MethodSelf-citationThe Quality of Life of Patients with End-Stage Renal Disease
Evans, R. W., Manninen, D. L., Garrison, L. P., Hart, L. G., Blagg, C. R., Gutman, R. A., Hull, A. R., & Lowrie, E. G. (1985) · New England Journal of Medicine · doi:10.1056/nejm198502283120905 · Cited by 1,183
Complement-Binding Anti-HLA Antibodies and Kidney-Allograft Survival
Loupy, A., Lefaucheur, C., Vernerey, D., Prugger, C., van Huyen, J.-P. D., Mooney, N., Suberbielle, C., Frémeaux-Bacchi, V., Méjean, A., Desgrandchamps, F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302506 · Cited by 852
Comparison of Survival Probabilities for Dialysis Patients vs Cadaveric Renal Transplant Recipients
Port, F. K. (1993) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1993.03510110079036 · Cited by 825
Preexisting Donor-Specific HLA Antibodies Predict Outcome in Kidney Transplantation
Lefaucheur, C., Loupy, A., Hill, G. S., Andrade, J., Nochy, D., Antoine, C., Gautreau, C., Charron, D., Glotz, D., & Suberbielle-Boissel, C. (2010) · Journal of the American Society of Nephrology · doi:10.1681/asn.2009101065 · Cited by 789
Rituximab and Intravenous Immune Globulin for Desensitization during Renal Transplantation
Vo, A. A., Lukovsky, M., Toyoda, M., Wang, J., Reinsmoen, N. L., Lai, C.-H., Peng, A., Villicana, R., & Jordan, S. C. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0707894 · Cited by 692
Self-citationDesensitization in HLA-Incompatible Kidney Recipients and Survival
Montgomery, R. A., Lonze, B. E., King, K. E., Kraus, E. S., Kucirka, L. M., Locke, J. E., Warren, D. S., Simpkins, C. E., Dagher, N. N., Singer, A. L., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1012376 · Cited by 687
IdeS, a novel streptococcal cysteine proteinase with unique specificity for immunoglobulin G
von Pawel-Rammingen, U. (2002) · The EMBO Journal · doi:10.1093/emboj/21.7.1607 · Cited by 473
Research works printed but not linked: 1
- 12. ies predict outcome in kidney transplantation. J Am Soc Nephrol 2010; 21: 1398406.
Cited by
Items 301–376 of 376
Imlifidase as a Potential Treatment for Antibody-Mediated Rejection
Huang, E., & Jordan, S. C. (2021) · Current Transplantation Reports · doi:10.1007/s40472-021-00327-0 · Cited by 1
Self-citationIgM single antigen bead HLA-assay is affected by imlifidase through the cleavage of IgG but not IgM
Runström, A., Sjöholm, K., Roupé, K. M., Lorant, T., Kjellman, C., & Bockermann, R. (2021) · Transplant Immunology · doi:10.1016/j.trim.2021.101436 · Cited by 1
Self-citationNeutrophil extracellular trap stabilization leads to improved outcomes in murine models of sepsisPreprint
Gollomp, K. L., Sarkar, A., Seeholzer, S. H., Rauova, L., Kowalska, M. A., & Poncz, M. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/630483 · Cited by 1
“Infusion with IdeS, a bacterial protease that cleaves the hinge region of heavy chain IgG and abolishes its ability to bind to Fc R, reduces the pathogenicity of autoantibodies in HIT, immune thrombocytopenia, and solid organ transplant 55-57 .”
BackgroundKidney Transplantation in Sensitized Patients
Acharya, S. J. (2021) · Indian Journal of Transplantation · doi:10.4103/ijot.ijot_4_21 · Cited by 1
Lan, J. H. (2024) · Journal of the American Society of Nephrology · doi:10.1681/asn.0000000000000302 · Cited by 1
Transplantation in the Sensitized Recipient and Across ABO Blood Groups
Schinstock, C. A., & Stegall, M. D. (2019) · Elsevier eBooks · doi:10.1016/b978-0-323-53186-3.00022-x
Burner, J. D., & Goldfinger, D. (2018) · Transfusion and Apheresis Science · doi:10.1016/j.transci.2018.05.024
New IDEaS for HIT treatment, anyone?
Padmanabhan, A. (2019) · Blood · doi:10.1182/blood.2019000695
Horn, E. T., & Demehin, M. (2019) · Organ and tissue transplantation · doi:10.1007/978-3-319-33280-2_39-1
The Role of Desensitization in Kidney Paired Donation
Pham, T., Lee, L., & Melcher, M. L. (2019) · Current Transplantation Reports · doi:10.1007/s40472-019-00261-2
Treatment of Rejection in Desensitized KT Patients
Kim, J.-K. (2019) · Springer eBooks · doi:10.1007/978-981-10-7046-4_7
Preoperative Management (Desensitization)
Kim, C. (2019) · Springer eBooks · doi:10.1007/978-981-10-7046-4_3
Overcoming Donor/Recipient Incompatibility
Vella, J. P., & Wiseman, A. C. (2019) · Nephrology Self-Assessment Program · doi:10.1681/nsap.2019.18.5.7
Management of Anti-HLA Antibodies and Acute Antibody-Mediated Rejection
Montgomery, R. A. (2020) · Springer eBooks · doi:10.1007/978-3-030-49127-7_10
Evolving Approaches to Treatment of Allosensitization and Antibody-Mediated Rejection
Jordan, S. C., Ammerman, N., & Vo, A. A. (2020) · Springer eBooks · doi:10.1007/978-3-030-49127-7_11
Self-citationSchön, S., Stendahl, M., Bell, M., Divino‐Filho, J. C., Rydell, H., Heimbürger, O., Lundgren, T., Segelmark, M., & Welander, G. (2021) · Springer eBooks · doi:10.1007/978-3-030-56890-0_48
Self-citationEguchi, S. (2021) · Hepatology Research · doi:10.1111/hepr.13694
Paixão, J. O. (2021) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.5.2021.tde-09092021-141139
Antibody mediated rejection. Evidence based medicine. What is the current evidence?
Menezes, M. D. M., Aires, I. D., & Nolasco, F. E. B. (2020) · Portuguese Journal of Nephrology & Hypertension · doi:10.32932/pjnh.2020.10.085
Nouvelles stratégies immunosuppressives en transplantation
Kervella, D., & Blancho, G. (2022) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/j.banm.2022.02.004
Simon‐Tillaux, N., & Chauvet, S. (2022) · La Presse Médicale Formation · doi:10.1016/j.lpmfor.2022.03.005
Kim, B. S., Lee, J., & Huh, K. H. (2019) · Springer eBooks · doi:10.1007/978-981-10-7046-4_9
Collin, M. (2019) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.735014265.793556175
Horn, E. T., & Demehin, M. (2020) · Organ and tissue transplantation · doi:10.1007/978-3-319-58054-8_39
Early Medical and Surgical Complications After Kidney Transplantation
Lim, W. H., & Pleass, H. C. C. (2022) · Wiley eBooks · doi:10.1002/9781119105954.ch58
Solid Organ Transplantation: Rejection, Immunosuppression, and Tolerance
Mannon, E. C., Wood, K. J., & Mannon, R. B. (2023) · Elsevier eBooks · doi:10.1016/b978-0-7020-8165-1.00089-7 · Cited by 1
Self-citationCurrent Strategies in Immune Modulation and Desensitization Protocols
Patel, J., & Coutance, G. (2023) · Wiley eBooks · doi:10.1002/9781119633884.ch10
Luo, Y., Wu, X., Cai, Z., Liu, F., Li, L., & Tu, Y. (2023) · Transplantation Proceedings · doi:10.1016/j.transproceed.2023.09.018
Desensitization in Solid Organ Transplantation
Ullah, A., & AlMeshari, K. A. (2023) · Biomedical engineering · doi:10.5772/intechopen.113262
Kidney transplantation: the recipient
(2024) · Elsevier eBooks · doi:10.1016/b978-0-443-23571-9.00018-9 · Cited by 1
Renal Replasman Tedavileri ‘Derlemeler’
Genek, D. G., Bardak, S., Merhametsiz, Ö., Yeter, H. H., Yaşar, E., Yayar, Ö., Atılgan, K. G., Eroğlu, E., Cebeci, E., Oruç, M., et al. (2022) · Akademisyen Kitabevi eBooks · doi:10.37609/akya.1022
Shaking Hands with Streptococcal Antibody-Degrading Enzymes for Clinical Use (Review)
Jain, S., Srivastava, S., Gulati, I., & Bhandari, K. (2024) · Applied Biochemistry and Microbiology · doi:10.1134/s0003683823602871
P2RX4 Inhibition: Finally, a Silver Bullet for Long-lived Plasma Cells Depletion?
Zorn, E. (2024) · Transplantation · doi:10.1097/tp.0000000000005085
Imlifidase – ein innovativer Therapieansatz in der Nephrologie
Mestekemper, A. N., & Schreiber, A. (2024) · Die Nephrologie · doi:10.1007/s11560-024-00744-z
Reply: The importance of disrupting complement activation in acute lung injury
Cleary, S. J., & Looney, M. R. (2024) · Journal of Clinical Investigation · doi:10.1172/jci182451
Imlifidase – eine neue Option in der Transplantation
Gäckler, A., & Schönfelder, K. (2024) · Die Nephrologie · doi:10.1007/s11560-024-00785-4
Shishido, Y., Tracy, K. M., Wu, W. K., Cortelli, M., Petrovic, M., Harris, T. R., Simon, V., Francois, S. A., Tucker, W. D., Petree, B. S., et al. (2024) · ASAIO Journal · doi:10.1097/mat.0000000000002311
“7 Furthermore, given the concern of possible cross-species antibody recognition, pharmacological strategies with IgG endo-peptidase 8 and anti-interleukin-2 receptor antibodies 9 could be added to the regimen to alleviate antibody-mediated cellular cytotoxicity and anti-porcine immune responses.”
Bestard, O., & Kervella, D. (2024) · Nephrology Self-Assessment Program · doi:10.58483/nsap.00332024
An IgM Cleaving Enzyme for Clearance of Anti‐Pig Xenoreactive Antibodies in a Nonhuman Primate Model
Martinino, A., Smith, T. J., Elmore, Z. C., Yoon, J., Ladowski, J. M., Schiliró, D., Hull, J. A., Schwalb, A., Hu, M., Spangler, R. D., et al. (2025) · Xenotransplantation · doi:10.1111/xen.70015 · Cited by 3
Transplantation Immunology: Kidney and liver
Trotter, P., McGovern, D., & Clatworthy, M. R. (2025) · Elsevier eBooks · doi:10.1016/b978-0-12-824465-4.00154-x
Overview of Transplantation Immunobiology
Zhang, X. (2025) · Springer eBooks · doi:10.1007/978-3-031-88290-6_6
Self-citationPaixão, J. O., Ulisses, L. R. D. S., Agena, F., de Souza, P. S., Bezerra, G., Rodriges, H., David‐Neto, E., & de Castro, M. C. R. (2026) · Medical Research Archives · doi:10.18103/mra.2026.0602
Dirix, M., Ceuleers, B., & de Fijter, J. W. (2025) · Wiley eBooks · doi:10.1002/9783527847617.ch10
Koh, H. B., & Yang, J. (2025) · Kidney Research and Clinical Practice · doi:10.23876/j.krcp.25.159
Intestinal reengineering: Scientific advances in intestinal transplantation
Rong, Y., Nie, C.-Y., Zhou, J.-D., Wang, Z., Wu, D. W., Wu, S.-W., & Xie, Z. (2025) · World Journal of Gastrointestinal Surgery · doi:10.4240/wjgs.v17.i10.111672 · Cited by 1
Renal Transplant in a Hypersensitive Patient: A Case Report
León-Rabanal, C., Montes, L. Z., Guerra-García, R. C. D. L. M., Dueñas-Chuquimia, J., Benites, E. M., & Valdez, A. (2025) · Open Journal of Nephrology · doi:10.4236/ojneph.2025.154047
Dudreuilh, C., Jarvis, P., Beadle, N., Pilecka, I., Shaw, O., Gardner, L., Scottà, C., Mamode, N., Game, D., Sanchez-Fueyo, A., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26585577
Eriyat, V., Reddy, Y., & Basu, G. (2025) · Springer eBooks · doi:10.1007/978-981-95-1533-2_19
Progress in Immunosuppressive Therapy for IgA Nephropathy
赵, 若. (2026) · Advances in Clinical Medicine · doi:10.12677/acm.2026.162412
Managing the highly sensitized kidney transplant patient
Jackson, K. R., & Parsons, R. F. (2026) · Current Opinion in Organ Transplantation · doi:10.1097/mot.0000000000001267
Establishment of Rat Model of Acute Antibody-Mediated Rejection in Kidney Transplantation
Qu, C., Yang, Z., Zhang, J., Liao, T., & Wang, J. (2026) · Journal of Visualized Experiments · doi:10.3791/69793 · Cited by 1
Sanmarco, L. M., Pellerin, A., Green, T., Plasencia, A., Anderson, J. M., Le, N., Newton, A., Chen, J. S., Ramello, M. C., Peckner, R., et al. (2026) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2518366123 · Cited by 1
Kizlik‐Masson, C. (2018) · theses.fr (ABES) · doi:10.70675/25332178z3663z43b5zb134z384f5624cda7
Deveuve, Q. (2020) · theses.fr (ABES) · doi:10.70675/0846fa89zb47dz41afzaa8bz1aba36466f1d
Blumberg, E. A., Gill, J., & Mannon, R. B. (2026) · American Journal of Transplantation · doi:10.1016/j.ajt.2026.03.032
Eradication of FVIII inhibitors in patients with hemophilia A
Bou-Jaoudeh, M. (2023) · theses.fr (ABES) · doi:10.70675/fb0159d0zb989z4a8dz9ca2zc27e4e44e055
Identification and Characterization of Novel Human IgG-Degrading Enzymes
Tran, E., Spraggon, G., Jones, D. H., & Appling, F. D. (2026) · Biochemistry · doi:10.1021/acs.biochem.6c00021
Petersen, M., Lin, J., Zhan, K., Anwar, P., Bockermann, R., & Anderson, C. C. (2026) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2026.04.017
Shen, C. K.-F., Liu, J., Xu, K., Xu, P., Li, Z., Li, W., Li, C., Ding, F., Xiao, C., Yao, X., et al. (2026) · Journal of Chromatography B · doi:10.1016/j.jchromb.2026.125111
Braga, B. G., Cunha, A., Almeida, M., Sousa, S., Trigo, F., Inácio, A. D. S., Dias, B., Silvano, J., Ribeiro, C. M. A., Pedroso, S., et al. (2026) · World Journal of Transplantation · doi:10.5500/wjt.v16.i2.115329
Nelson, S. E., Martinusen, S. G., Pho, R., Long, L. F., & Denard, C. A. (2026) · Biochemical Journal · doi:10.1042/bcj20260152
“IdeS (imlifidase), an IgG-degrading cysteine endopeptidase from Streptococcus pyogenes , cleaves the Fc region of IgG antibodies, blocking FcRn interactions and interfering with immune activation (Figure 2) [42,43].”
Patel, M., & Dholakia, A. (2026) · International Journal of Research in Medical Sciences · doi:10.18203/2320-6012.ijrms20261857
Xu, N., Dong, Y., Yue, Y., & Zhou, L. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1902286 · Cited by 1
“It has demonstrated rapid DSA clearance in desensitization, but its effect is transient and does not suppress antibody re − production (161).”
The new era of treatments for kidney transplant recipients
Junior, H. T. S. (2026) · Brazilian Journal of Nephrology · doi:10.1590/2175-8239-jbn-2026-0018en
“%) with limited likelihood of receiving an HLA-compatible transplant 9,10 .”
A nova era dos tratamentos para receptores de transplante renal
Junior, H. T. S. (2026) · Brazilian Journal of Nephrology · doi:10.1590/2175-8239-jbn-2026-0018pt
Reshaping the landscape of HLA desensitization through immune engineering
Kervella, D., & Bestard, O. (2026) · Transplant International · doi:10.3389/ti.2026.17609
Li, K., Qi, H., 信瑶瑶, Qin, L., Cheng, Y., & Yao, X. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1930837
“Imlifidase (IdeS) is already clinically validated in a different context, having enabled transplantation in highly sensitized recipients (Jordan et al., 2017).”
Delisting strategies in highly sensitized kidney transplant candidates
D’Angelo, M., Zahrádka, I., Jaklova, K., Maggiore, U., & Viklicky, O. (2026) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfag229
Lei, Y., 郑如莹, & Zhao, D. (2026) · Genes · doi:10.3390/genes17101270
Ramírez-Larrota, J. S., Arasa, G., López-Martín, M., Effantin, G., Gragera, M., Sorzano, C. Ó. S., Marcos, E., Eckhard, U., & Gomis‐Rüth, F. X. (2026) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2626241123
IgM-and IgG-cleaving enzyme facilitates AAV gene transfer in AAV-seropositive macaques
Wu, H. L., Elmore, Z. C., Ochoa, M. A., McCullen, A. J., Brown, M. K., Fisher, H. K., Potter, S. K., Mott, M. G. E., Hull, J. A., Fuchs, S. P., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1966044
Advances in HLA desensitization for kidney transplant candidates
Chandran, S., Huang, E., Vo, A. A., & Jordan, S. C. (2026) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000001231
Self-citation
Metadata
- Authors
- Jordan, S. C., Lorant, T., Choi, J., Kjellman, C., Winstedt, L., Bengtsson, M., Zhang, X., Eich, T., Toyoda, M., Eriksson, B.-M., Ge, S., Peng, A., Järnum, S., Wood, K. J., Lundgren, T., Wennberg, L., Bäckman, L., Larsson, E., Villicana, R., Kahwaji, J., Louie, S., Kang, A., Haas, M., Nast, C., Vo, A., & Tufveson, G.
- Affiliations
- Uppsala University (SE)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-08-03
- Volume
- 377
- Issue
- 5
- Pages
- 442-453
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2740266422
- Cited by
- 377
- References
- 30
- Citations by year
- 2026: 32 · 2025: 44 · 2024: 37 · 2023: 50 · 2022: 45 · 2021: 39 · 2020: 38 · 2019: 45 · 2018: 36 · 2017: 11
- FWCI
- 30.04
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Transplantation › Renal Transplantation Outcomes and Treatments
- Health Sciences › Medicine › Surgery › Transplantation: Methods and Outcomes
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Keywords
- ide, HLA sensitization, kidney transplantation, desensitization, donor-specific antibodies, antibody-mediated rejection, cold ischemia time, delayed graft function, adverse events, antibody rebound
- MeSH terms
- Adult, Antibodies, Bacterial Proteins, Cysteine Endopeptidases, Female, Histocompatibility Testing, HLA Antigens, Humans, Immunoglobulin G, Immunosuppression Therapy, Male, Middle Aged, Transplantation Immunology, Complement C1q, Kidney Transplantation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.